Suppr超能文献

人类胃肠道癌症中体细胞突变的免疫原性。

Immunogenicity of somatic mutations in human gastrointestinal cancers.

作者信息

Tran Eric, Ahmadzadeh Mojgan, Lu Yong-Chen, Gros Alena, Turcotte Simon, Robbins Paul F, Gartner Jared J, Zheng Zhili, Li Yong F, Ray Satyajit, Wunderlich John R, Somerville Robert P, Rosenberg Steven A

机构信息

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.

Abstract

It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor from CD8(+) TILs that targeted the KRAS(G12D) hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies.

摘要

目前尚不清楚人类免疫系统是否经常对常见上皮癌所表达的突变产生T细胞反应。通过将新一代测序方法与高通量免疫筛选相结合,我们证明,10例转移性胃肠道癌患者中有9例的肿瘤浸润淋巴细胞(TIL)含有CD4(+)和/或CD8(+) T细胞,这些T细胞识别出一至三个源自患者自身肿瘤所表达的体细胞突变的新抗原表位。这些患者之间不存在共享的免疫原性表位。然而,我们在一名患者中从CD8(+) TIL中鉴定出一种人类白细胞抗原-C*08:02限制性T细胞受体,该受体靶向在许多人类癌症中发现的KRAS(G12D)热点驱动突变。因此,常见胃肠道癌患者中很大一部分携带免疫原性突变,这些突变有可能被用于开发高度个性化的免疫疗法。

相似文献

1
Immunogenicity of somatic mutations in human gastrointestinal cancers.
Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.
3
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
Clin Cancer Res. 2014 Jan 15;20(2):331-43. doi: 10.1158/1078-0432.CCR-13-1736. Epub 2013 Nov 11.
4
T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H.
Front Immunol. 2025 Mar 17;16:1509855. doi: 10.3389/fimmu.2025.1509855. eCollection 2025.
5
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12826-12835. doi: 10.1073/pnas.1921964117. Epub 2020 May 27.
8
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.
Clin Cancer Res. 2017 Aug 1;23(15):4347-4353. doi: 10.1158/1078-0432.CCR-16-1423. Epub 2017 Apr 4.
9
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.
Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.
10
Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through development.
Oncol Res. 2024 Nov 13;32(12):1837-1850. doi: 10.32604/or.2024.056565. eCollection 2024.

引用本文的文献

1
Immunologic specificity in glioblastoma: Antigen discovery and translational implications.
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv41-iv70. doi: 10.1093/noajnl/vdaf028. eCollection 2025 Sep.
2
Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics.
Nat Commun. 2025 Aug 7;16(1):7269. doi: 10.1038/s41467-025-62647-4.
3
Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC.
NPJ Precis Oncol. 2025 Aug 2;9(1):271. doi: 10.1038/s41698-025-01056-8.
5
Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer.
Mol Ther Methods Clin Dev. 2025 Jun 18;33(3):101517. doi: 10.1016/j.omtm.2025.101517. eCollection 2025 Sep 11.
6
Efficient and effective identification of cancer neoantigens from tumor only RNA-seq.
NAR Genom Bioinform. 2025 Jul 11;7(3):lqaf026. doi: 10.1093/nargab/lqaf026. eCollection 2025 Sep.
7
Eliciting antitumor immunity via therapeutic cancer vaccines.
Cell Mol Immunol. 2025 Jul 9. doi: 10.1038/s41423-025-01316-4.
8
The challenges and progress of CAR-T cell therapy in the treatment of solid tumors.
Mol Cell Biochem. 2025 Jun 23. doi: 10.1007/s11010-025-05329-5.
9
Identification of shared neoantigens derived from frameshift mutations in the gene.
Front Immunol. 2025 May 15;16:1574955. doi: 10.3389/fimmu.2025.1574955. eCollection 2025.
10
Bispecific antibody targeting shared indel-derived neoantigen of APC.
Front Immunol. 2025 May 15;16:1574958. doi: 10.3389/fimmu.2025.1574958. eCollection 2025.

本文引用的文献

1
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
2
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
3
Adoptive cell transfer as personalized immunotherapy for human cancer.
Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967.
4
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
5
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19.
6
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.
7
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.
8
API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.
Cancer Res. 2014 Jul 1;74(13):3556-66. doi: 10.1158/0008-5472.CAN-13-3225. Epub 2014 Apr 25.
9
KRAS: feeding pancreatic cancer proliferation.
Trends Biochem Sci. 2014 Feb;39(2):91-100. doi: 10.1016/j.tibs.2013.12.004. Epub 2014 Jan 2.
10
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
J Clin Oncol. 2013 Nov 10;31(32):e439-42. doi: 10.1200/JCO.2012.47.7521. Epub 2013 Sep 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验